Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study

IF 5.5 2区 医学 Q1 HEMATOLOGY Journal of Thrombosis and Haemostasis Pub Date : 2024-09-01 DOI:10.1016/j.jtha.2024.07.019
Simon Kraler , Luca Liberale , Stephan Nopp , Cornelia Englisch , Ella Grilz , Tetiana Lapikova-Bryhinska , Alexander Akhmedov , Federico Carbone , Davide Ramoni , Amedeo Tirandi , Alessandro Scuricini , Simone Isoppo , Curzia Tortorella , Federica La Rosa , Cristina Michelauz , Federica Frè , Aurora Gavoci , Anna Lisa , Thomas M. Suter , Arnold von Eckardstein , Florian Moik
{"title":"Biomarker-enhanced cardiovascular risk prediction in patients with cancer: a prospective cohort study","authors":"Simon Kraler ,&nbsp;Luca Liberale ,&nbsp;Stephan Nopp ,&nbsp;Cornelia Englisch ,&nbsp;Ella Grilz ,&nbsp;Tetiana Lapikova-Bryhinska ,&nbsp;Alexander Akhmedov ,&nbsp;Federico Carbone ,&nbsp;Davide Ramoni ,&nbsp;Amedeo Tirandi ,&nbsp;Alessandro Scuricini ,&nbsp;Simone Isoppo ,&nbsp;Curzia Tortorella ,&nbsp;Federica La Rosa ,&nbsp;Cristina Michelauz ,&nbsp;Federica Frè ,&nbsp;Aurora Gavoci ,&nbsp;Anna Lisa ,&nbsp;Thomas M. Suter ,&nbsp;Arnold von Eckardstein ,&nbsp;Florian Moik","doi":"10.1016/j.jtha.2024.07.019","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Continuously improving cancer-specific survival puts a growing proportion of cancer patients at risk of major adverse cardiovascular events (MACE), but tailored tools for cardiovascular risk prediction remain unavailable.</div></div><div><h3>Objectives</h3><div>To assess a broad panel of cardiovascular biomarkers and risk factors for the prediction of MACE and cardiovascular death in cancer patients.</div></div><div><h3>Methods</h3><div>In total, 2192 patients with newly diagnosed or recurrent cancer were followed prospectively for the occurrence of 2-year MACE and 5-year cardiovascular death. Univariable and multivariable risk models were fit to assess independent associations of cardiovascular risk factors and biomarkers with adverse outcomes, and a risk score was developed.</div></div><div><h3>Results</h3><div>Traditional cardiovascular risk factors and selected cancer types were linked to higher MACE risk. While levels of Lp(a), CRP, and GDF-15 did not associate with MACE, levels of ICAM-1, P-/E-/L-selectins, and NT-proBNP were independently linked to 2-year MACE risk. A clinical risk score was derived, assigning +1 point for male sex, smoking, and age of ≥60 years and +2 points for atherosclerotic disease, yielding a bootstrapped <em>C</em>-statistic of 0.76 (95% CI: 0.71-0.81) for the prediction of 2-year MACE. Implementation of biomarker data conferred improved performance (0.83, 95% CI: 0.78-0.88), with a simplified model showing similar performance (0.80, 95% CI: 0.74-0.86). The biomarker-enhanced and simplified prediction models achieved a <em>C</em>-statistic of 0.82 (95% CI: 0.71-0.93) and 0.74 (95% CI: 0.64-0.83) for the prediction of 5-year cardiovascular death.</div></div><div><h3>Conclusion</h3><div>Biomarker-enhanced risk prediction strategies allow the identification of cancer patients at high risk of MACE and cardiovascular death. While external validation studies are ongoing, this <em>first-of-its-kind</em> risk score may provide the basis for personalized cardiovascular risk assessment across cancer entities.</div></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":null,"pages":null},"PeriodicalIF":5.5000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538783624004367","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Continuously improving cancer-specific survival puts a growing proportion of cancer patients at risk of major adverse cardiovascular events (MACE), but tailored tools for cardiovascular risk prediction remain unavailable.

Objectives

To assess a broad panel of cardiovascular biomarkers and risk factors for the prediction of MACE and cardiovascular death in cancer patients.

Methods

In total, 2192 patients with newly diagnosed or recurrent cancer were followed prospectively for the occurrence of 2-year MACE and 5-year cardiovascular death. Univariable and multivariable risk models were fit to assess independent associations of cardiovascular risk factors and biomarkers with adverse outcomes, and a risk score was developed.

Results

Traditional cardiovascular risk factors and selected cancer types were linked to higher MACE risk. While levels of Lp(a), CRP, and GDF-15 did not associate with MACE, levels of ICAM-1, P-/E-/L-selectins, and NT-proBNP were independently linked to 2-year MACE risk. A clinical risk score was derived, assigning +1 point for male sex, smoking, and age of ≥60 years and +2 points for atherosclerotic disease, yielding a bootstrapped C-statistic of 0.76 (95% CI: 0.71-0.81) for the prediction of 2-year MACE. Implementation of biomarker data conferred improved performance (0.83, 95% CI: 0.78-0.88), with a simplified model showing similar performance (0.80, 95% CI: 0.74-0.86). The biomarker-enhanced and simplified prediction models achieved a C-statistic of 0.82 (95% CI: 0.71-0.93) and 0.74 (95% CI: 0.64-0.83) for the prediction of 5-year cardiovascular death.

Conclusion

Biomarker-enhanced risk prediction strategies allow the identification of cancer patients at high risk of MACE and cardiovascular death. While external validation studies are ongoing, this first-of-its-kind risk score may provide the basis for personalized cardiovascular risk assessment across cancer entities.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症患者生物标志物增强心血管风险预测:一项前瞻性队列研究。
背景:癌症特异性生存率的不断提高使越来越多的癌症患者面临重大不良心血管事件(MACE)的风险,但目前仍缺乏量身定制的心血管风险预测工具:评估一系列心血管生物标志物和风险因素,以预测癌症患者的 MACE 和心血管死亡:方法:共对2192名新确诊或复发癌症患者进行了前瞻性随访,以观察2年MACE和5年心血管死亡的发生情况。拟合了单变量和多变量风险模型,以评估心血管风险因素和生物标志物与不良结局的独立关联,并制定了风险评分:结果:传统的心血管风险因素和某些癌症类型与较高的MACE风险有关。虽然脂蛋白(a)、CRP和GDF-15的水平与MACE无关,但ICAM-1、P-/E-/L-选择素和NT-proBNP的水平与2年MACE风险独立相关。得出的临床风险评分为:男性、吸烟和年龄≥60 岁+1 分,动脉粥样硬化性疾病+2 分,预测 2 年 MACE 的自引导 C 统计量为 0.76(95% CI:0.71-0.81)。生物标志物数据的应用提高了预测效果(0.83,95% CI:0.78-0.88),简化模型的预测效果与之相似(0.80,95% CI:0.74-0.86)。在预测5年心血管死亡方面,生物标志物增强预测模型和简化预测模型的C统计量分别为0.82(95% CI:0.71-0.93)和0.74(95% CI:0.64-0.83):结论:生物标志物增强风险预测策略可识别出MACE和心血管死亡风险较高的癌症患者。虽然外部验证研究仍在进行中,但这一首创的风险评分可为跨癌症实体的个性化心血管风险评估奠定基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis 医学-外周血管病
CiteScore
24.30
自引率
3.80%
发文量
321
审稿时长
1 months
期刊介绍: The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community. Types of Publications: The journal publishes a variety of content, including: Original research reports State-of-the-art reviews Brief reports Case reports Invited commentaries on publications in the Journal Forum articles Correspondence Announcements Scope of Contributions: Editors invite contributions from both fundamental and clinical domains. These include: Basic manuscripts on blood coagulation and fibrinolysis Studies on proteins and reactions related to thrombosis and haemostasis Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.
期刊最新文献
An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: Guidance from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. The severe von Willebrand Disease variant p.M771V leads to impaired anterograde trafficking of Von Willebrand factor in patient-derived and base-edited ECFCs. Validating International Classification of Diseases Code 10th Revision algorithms for accurate identification of pulmonary embolism. High risk of long-term recurrence after a first episode of venous thromboembolism during pregnancy or postpartum: the REcurrence after a PrEgnAncy related Thrombosis (REPEAT) Study. Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1